Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2004 3
2005 1
2006 2
2007 4
2008 8
2009 8
2010 8
2011 3
2012 11
2013 7
2014 13
2015 13
2016 12
2017 12
2018 14
2019 6
2020 10
2021 35
2022 18
2023 16

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
Cheifetz AS, Abreu MT, Afif W, Cross RK, Dubinsky MC, Loftus EV Jr, Osterman MT, Saroufim A, Siegel CA, Yarur AJ, Melmed GY, Papamichael K. Cheifetz AS, et al. Among authors: melmed gy. Am J Gastroenterol. 2021 Oct 1;116(10):2014-2025. doi: 10.14309/ajg.0000000000001396. Am J Gastroenterol. 2021. PMID: 34388143 Free PMC article. Review.
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Papamichael K, et al. Among authors: melmed gy. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1655-1668.e3. doi: 10.1016/j.cgh.2019.03.037. Epub 2019 Mar 27. Clin Gastroenterol Hepatol. 2019. PMID: 30928454 Free PMC article.
Melmed GY, Cohen ER. Melmed GY, et al. Clin Gastroenterol Hepatol. 2018 Nov;16(11):1840. doi: 10.1016/j.cgh.2018.07.005. Clin Gastroenterol Hepatol. 2018. PMID: 30343867 No abstract available.
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
Siegel CA, Melmed GY, McGovern DP, Rai V, Krammer F, Rubin DT, Abreu MT, Dubinsky MC; International Organization for the Study of Inflammatory Bowel Disease (IOIBD); International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). Siegel CA, et al. Among authors: melmed gy. Gut. 2021 Apr;70(4):635-640. doi: 10.1136/gutjnl-2020-324000. Epub 2021 Jan 20. Gut. 2021. PMID: 33472895 Free PMC article. No abstract available.
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis.
Panaccione R, Collins EB, Melmed GY, Vermeire S, Danese S, Higgins PDR, Kwon CS, Zhou W, Ilo D, Sharma D, Sanchez Gonzalez Y, Wang ST. Panaccione R, et al. Among authors: melmed gy. Crohns Colitis 360. 2023 Mar 1;5(2):otad009. doi: 10.1093/crocol/otad009. eCollection 2023 Apr. Crohns Colitis 360. 2023. PMID: 36998249 Free PMC article.
Certolizumab pegol.
Melmed GY, Targan SR, Yasothan U, Hanicq D, Kirkpatrick P. Melmed GY, et al. Nat Rev Drug Discov. 2008 Aug;7(8):641-2. doi: 10.1038/nrd2654. Nat Rev Drug Discov. 2008. PMID: 18670430
Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
Gu P, Luo J, Kim J, Paul P, Limketkai B, Sauk JS, Park S, Parekh N, Zheng K, Rudrapatna V, Syal G, Ha C, McGovern DP, Melmed GY, Fleshner P, Eisenstein S, Ramamoorthy S, Dulai PS, Boland BS, Grunvald E, Mahadevan U, Ohno-Machado L, Sandborn WJ, Singh S. Gu P, et al. Among authors: melmed gy. Am J Gastroenterol. 2022 Oct 1;117(10):1639-1647. doi: 10.14309/ajg.0000000000001855. Epub 2022 Jun 7. Am J Gastroenterol. 2022. PMID: 35973139
Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
Akhlaghpour M, Haritunians T, More SK, Thomas LS, Stamps DT, Dube S, Li D, Yang S, Landers CJ, Mengesha E, Hamade H, Murali R, Potdar AA, Wolf AJ, Botwin GJ, Khrom M; International IBD Genetics Consortium; Ananthakrishnan AN, Faubion WA, Jabri B, Lira SA, Newberry RD, Sandler RS, Sartor RB, Xavier RJ, Brant SR, Cho JH, Duerr RH, Lazarev MG, Rioux JD, Schumm LP, Silverberg MS, Zaghiyan K, Fleshner P, Melmed GY, Vasiliauskas EA, Ha C, Rabizadeh S, Syal G, Bonthala NN, Ziring DA, Targan SR, Long MD, McGovern DPB, Michelsen KS. Akhlaghpour M, et al. Among authors: melmed gy. Gut. 2023 Apr 20:gutjnl-2023-329689. doi: 10.1136/gutjnl-2023-329689. Online ahead of print. Gut. 2023. PMID: 37080587 Free article.
Quality indicators in inflammatory bowel disease.
Berry SK, Melmed GY. Berry SK, et al. Among authors: melmed gy. Intest Res. 2018 Jan;16(1):43-47. doi: 10.5217/ir.2018.16.1.43. Epub 2018 Jan 18. Intest Res. 2018. PMID: 29422796 Free PMC article. Review.
181 results